Literature DB >> 29870114

Emerging Trends in Clinical Research: With Implications for Population Health and Health Policy.

Benjamin Chin-Yee1,2, S V Subramanian3,4, Amol A Verma1,2,5, Andreas Laupacis1,2,5,6, Fahad Razak1,2,3,5,6.   

Abstract

Policy Points: Significant advances in clinical medicine that have broader societal relevance may be less accessible to population health researchers and policymakers because of increased specialization within fields. We describe important recent clinical advances and discuss their broader societal impact. These advances include more expansive strategies for disease prevention, the rise of precision medicine, applications of human microbiome research, and new and highly successful treatments for hepatitis C infection. These recent developments in clinical research raise important issues surrounding health care costs and equitable resource allocation that necessitate an ongoing dialogue among the fields of clinical medicine, population health, and health policy. CONTEXT: Developments in clinical medicine have important implications for population health, and there is a need for interdisciplinary engagement among clinical medicine, the social sciences, and public health research. The aim of this article is to help bridge the divide between these fields by exploring major recent advances in clinical medicine that have important implications for population health.
METHODS: We reviewed the most cited articles published from 2010 to 2015 in 5 high-impact clinical journals and selected 5 randomized controlled trials and 2 related clinical practice guidelines that are broadly relevant to population health and policy.
FINDINGS: We discuss the following themes: (1) expanding indications for drug therapy and the inherent medicalization of the population as highlighted by studies and clinical guidelines supporting lower blood pressure targets or widespread statin use; (2) the tension in nutritional research between quantifying the impact of isolated nutrients and studying specific foods and dietary patterns, for example, the role of the Mediterranean diet in the primary prevention of cardiovascular disease; (3) the issue of high medication costs and the challenge of providing equitable access raised by the development of new and effective treatments for hepatitis C infection; (4) emerging clinical applications of research on the human microbiome as illustrated by fecal transplant to treat Clostridium difficile infections; and (5) the promise and limitations of precision medicine as demonstrated by the rise of novel targeted therapies in oncology.
CONCLUSIONS: These developments in clinical science hold promise for improving individual and population health and raise important questions about resource allocation, the role of prevention, and health disparities.
© 2018 Milbank Memorial Fund.

Entities:  

Keywords:  clinical trials; drug costs; health equity; public health; social sciences

Mesh:

Year:  2018        PMID: 29870114      PMCID: PMC5987824          DOI: 10.1111/1468-0009.12328

Source DB:  PubMed          Journal:  Milbank Q        ISSN: 0887-378X            Impact factor:   4.911


  143 in total

1.  Selling sickness: the pharmaceutical industry and disease mongering.

Authors:  Ray Moynihan; Iona Heath; David Henry
Journal:  BMJ       Date:  2002-04-13

2.  Public Health in the Precision-Medicine Era.

Authors:  Ronald Bayer; Sandro Galea
Journal:  N Engl J Med       Date:  2015-08-06       Impact factor: 91.245

3.  Polypills: essential medicines for cardiovascular disease secondary prevention?

Authors:  Mark D Huffman; Salim Yusuf
Journal:  J Am Coll Cardiol       Date:  2014-02-19       Impact factor: 24.094

4.  NCI-MATCH launch highlights new trial design in precision-medicine era.

Authors:  Caroline McNeil
Journal:  J Natl Cancer Inst       Date:  2015-07-03       Impact factor: 13.506

5.  Fecal microbiota transplantation--an old therapy comes of age.

Authors:  Ciarán P Kelly
Journal:  N Engl J Med       Date:  2013-01-16       Impact factor: 91.245

6.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

7.  Knowledge for Precision Medicine: Mechanistic Reasoning and Methodological Pluralism.

Authors:  Mark R Tonelli; Brian H Shirts
Journal:  JAMA       Date:  2017-11-07       Impact factor: 56.272

Review 8.  Clostridium difficile infection: epidemiology, diagnosis and understanding transmission.

Authors:  Jessica S H Martin; Tanya M Monaghan; Mark H Wilcox
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-03-09       Impact factor: 46.802

9.  Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants.

Authors: 
Journal:  Lancet       Date:  2016-11-16       Impact factor: 79.321

10.  Beverages Sales in Mexico before and after Implementation of a Sugar Sweetened Beverage Tax.

Authors:  M A Colchero; Carlos Manuel Guerrero-López; Mariana Molina; Juan Angel Rivera
Journal:  PLoS One       Date:  2016-09-26       Impact factor: 3.240

View more
  3 in total

1.  Reducing the Clinical Medicine and Population Health Divide.

Authors:  Sandro Galea
Journal:  Milbank Q       Date:  2018-09       Impact factor: 4.911

2.  Identifying subgroups of high-need, high-cost, chronically ill patients in primary care: A latent class analysis.

Authors:  Rowan G M Smeets; Arianne M J Elissen; Mariëlle E A L Kroese; Niels Hameleers; Dirk Ruwaard
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240

Review 3.  Governing Personalized Health: A Scoping Review.

Authors:  Philipp Trein; Joël Wagner
Journal:  Front Genet       Date:  2021-04-21       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.